AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes
The contract manufacturer will produce Tzield, an approved treatment that delays the onset of stage 3 type 1 diabetes, for Provention Bio, which secured rights from Lilly’s partner in 2018.
by albert rønning-andersson, translated by daniel pedersen
Contract development and manufacturing organization AGC Biologics will produce Provention Bio’s Tzield (teplizumab-mzwv), which was approved as a type 1 diabetes treatment by the US Food and Drug Administration (FDA) in November.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
AGC Biologics breaks ground on USD 190m Danish factory
For subscribers
.jpg&w=384&q=75)
